Gemcabene calcium | CAS#183293-82-5

MedKoo Cat#: 525160 | Name: Gemcabene calcium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gemcabene is a lipid-lowering small molecule to be used as an adjunctive therapy to reduce LDL-C, hsCRP, and TGs. Gemcabene is a first-in-class oral drug candidate with pleiotropic properties similar to statins as shown in trials to date. Gemcabene has a unique mechanism of action that involves the: (1) blocking the production of hepatic triglyceride and cholesterol synthesis; and (2) enhancing the clearance of VLDL by decreasing ApoC-III.

Chemical Structure

Gemcabene calcium

CAS#209789-08-2 (calcium)

Theoretical Analysis

MedKoo Cat#: 525160

Name: Gemcabene calcium

CAS#: 209789-08-2 (calcium)

Chemical Formula: C16H28CaO5

Exact Mass: 302.2093

Molecular Weight: 340.47

Elemental Analysis: C, 56.44; H, 8.29; Ca, 11.77; O, 23.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

209789-08-2 (calcium) 183293-82-5 (free base)

Synonym

Gemcabene; Gemcabene [INN]; PD 72953; PD-72953.

IUPAC/Chemical Name

calcium 6,6'-oxybis(2,2-dimethylhexanoate)

InChi Key

ZJKZKKPIKDNHDM-UHFFFAOYSA-L

InChi Code

InChI=1S/C16H30O5.Ca/c1-15(2,13(17)18)9-5-7-11-21-12-8-6-10-16(3,4)14(19)20;/h5-12H2,1-4H3,(H,17,18)(H,19,20);/q;+2/p-2

SMILES Code

O=C([O-])C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O.[Ca+2]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 340.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Goodman MD, McPartland S, Huber K, Saif MW. New developments in the management of borderline resectable pancreatic cancers. JOP. 2013 Jul 10;14(4):334-6. doi: 10.6092/1590-8577/1681. PubMed PMID: 23846921. 2: Gagnon J, Anini Y. Glucagon stimulates ghrelin secretion through the activation of MAPK and EPAC and potentiates the effect of norepinephrine. Endocrinology. 2013 Feb;154(2):666-74. doi: 10.1210/en.2012-1994. Epub 2013 Jan 10. PubMed PMID: 23307791. 3: Yuan H, Feng B, Yu Y, Chupka J, Zheng JY, Heath TG, Bond BR. Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther. 2009 Jul;330(1):191-7. doi: 10.1124/jpet.108.149476. Epub 2009 Apr 6. PubMed PMID: 19349522. 4: Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, Myrand SP. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol. 2007 Oct;64(4):458-68. Epub 2007 Jun 6. PubMed PMID: 17555467; PubMed Central PMCID: PMC2048551. 5: Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R. Model-based drug development. Clin Pharmacol Ther. 2007 Jul;82(1):21-32. Epub 2007 May 23. Review. PubMed PMID: 17522597. 6: Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22. Review. PubMed PMID: 16353929; PubMed Central PMCID: PMC2751254. 7: Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst SI, Menning LC, Milad M, Court MH, Williams JA. Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. Drug Metab Dispos. 2005 Sep;33(9):1349-54. Epub 2005 Jun 24. PubMed PMID: 15980101. 8: Bays H, Stein EA. Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother. 2003 Nov;4(11):1901-38. Review. PubMed PMID: 14596646. 9: Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE; Gemcabene Study Group. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003 Sep 1;92(5):538-43. PubMed PMID: 12943873. 10: Suckling K. Pharmacological modification of lipoprotein(a). Biochem Soc Trans. 1999 Aug;27(4):466-9. Review. PubMed PMID: 10917622. 11: Huang NH, Kagel JR, Rossi DT. Automated solid-phase extraction workstations combined with quantitative bioanalytical LC/MS. J Pharm Biomed Anal. 1999 Mar;19(3-4):613-20. PubMed PMID: 10704127. 12: Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, Newton RS. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res. 1998 Jan;39(1):17-30. Erratum in: J Lipid Res 1998 Jun;39(6):1317. PubMed PMID: 9469582.